Ugur Sahin Sells 34,000 Shares of BioNTech (NASDAQ:BNTX) Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 34,000 shares of the stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $98.60, for a total transaction of $3,352,400.00. Following the sale, the chief executive officer directly owned 519,209 shares in the company, valued at approximately $51,194,007.40. The trade was a 6.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total value of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total value of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total transaction of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total transaction of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Price Performance

BioNTech stock traded down $2.60 during midday trading on Friday, reaching $96.06. The company had a trading volume of 1,150,292 shares, compared to its average volume of 1,102,362. The company has a market capitalization of $24.29 billion, a P/E ratio of -12.27 and a beta of 1.29. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The firm’s fifty day simple moving average is $97.29 and its 200-day simple moving average is $94.92. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.BioNTech’s quarterly revenue was down 59.5% on a year-over-year basis. During the same quarter last year, the firm posted ($1.60) earnings per share. As a group, equities analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Monaco Asset Management SAM purchased a new stake in shares of BioNTech during the 4th quarter valued at approximately $1,594,000. Hsbc Holdings PLC purchased a new position in BioNTech in the fourth quarter worth approximately $4,969,000. Bank of America Corp DE grew its position in BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after acquiring an additional 166,432 shares during the period. BNP Paribas Financial Markets increased its stake in BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after acquiring an additional 474,796 shares during the last quarter. Finally, Amundi increased its stake in BioNTech by 24.5% during the first quarter. Amundi now owns 129,513 shares of the company’s stock worth $11,511,000 after acquiring an additional 25,506 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BNTX. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a report on Monday, June 1st. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Citigroup dropped their price objective on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. Finally, Berenberg Bank set a $140.00 target price on shares of BioNTech in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, BioNTech has an average rating of “Moderate Buy” and a consensus target price of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.